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esponsibility of InstAbstract We have shown recently that concurrent harmaline, a monoamine oxidase-A inhibitor
(MAOI), potentiates serotonin (5-HT) receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-
MeO-DMT)-induced hyperthermia. The objective of this study was to develop an integrated
pharmacokinetic/pharmacodynamic (PK/PD) model to characterize and predict the thermoregula-
tory effects of such serotonergic drugs in mice. Physiological thermoregulation was described by a
mechanism-based indirect-response model with adaptive feedback control. Harmaline-induced
hypothermia and 5-MeO-DMT–elicited hyperthermia were attributable to the loss of heat through
the activation of 5-HT1A receptor and thermogenesis via the stimulation of 5-HT2A receptor,
respectively. Thus serotonergic 5-MeO-DMT–induced hyperthermia was readily distinguished from
handling/injection stress-provoked hyperthermic effects. This PK/PD model was able to simulta-
neously describe all experimental data including the impact of drug-metabolizing enzyme status on
5-MeO-DMT and harmaline PK properties, and drug- and stress-induced simple hypo/hyperthermic
and complex biphasic effects. Furthermore, the modeling results revealed a 4-fold decrease of7
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le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Thermoregulatory effects of serotonergic drugs in mice 493apparent SC50 value (1.88–0.496 mmol/L) for 5-MeO-DMT when harmaline was co-administered,
providing a quantitative assessment for the impact of concurrent MAOI harmaline on 5-MeO-
DMT–induced hyperthermia. In addition, the hyperpyrexia caused by toxic dose combinations of
harmaline and 5-MeO-DMT were linked to the increased systemic exposure to harmaline rather than
5-MeO-DMT, although the body temperature proﬁles were mispredicted by the model. The results
indicate that current PK/PD model may be used as a new conceptual framework to deﬁne the impact
of serotonergic agents and stress factors on thermoregulation.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of
Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thermoregulation is a critical process in all mammals that requires
a ﬁne balance between heat production and heat loss1. Heat
production is achieved by contracting skeletal muscles (shivering
thermogenesis) and metabolic activities (non-shivering thermo-
genesis), such as metabolism of interscapular brown adipose tissue
(iBAT). Heat loss, on the other hand, is modulated by vasocon-
striction and vasodilation2,3. As a result, body temperature is
controlled by a number of systems including central, energetic,
metabolic and endocrine systems. Other factors including circadian
rhythm, gender or aging as well as ambient temperature may affect
thermoregulatory adjustments4–6. Central thermoregulation is
primarily controlled by the hypothalamus, where serotonergic
system plays an important role5,7. Stimulation of different
5-hydroxytryptamine (5-HT or serotonin) receptors mechanisti-
cally causes divergent effects on thermoregulation. Hypothermia
can be induced by 5-HT precursor tryptophan, monoamine
oxidase-A (MAO-A) inhibitor (MAOI) harmaline, 5-HT1A recep-
tor agonists such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-
OH-DPAT), and lower doses of 5-HT releaser 3,4-methylene-
dioxy-N-methylamphetamine (MDMA), which may be suppressed
by 5-HT1A receptor antagonist or small interfering RNA
(siRNA)8–10. On the other hand, 5-HT2 receptor agonists such as
2,5-dimethoxy-4-iodoamphetamine (DOI) and high doses of
MDMA induce hyperthermia in rats, which may be attenuated
by 5-HT2A receptor antagonists
11–14. In addition, pretreatment
with 5-HT1A agonist 8-OH-DPAT abolishes the hyperthermia
induced by 5-HT2A receptor agonist DOI, suggesting a function-
ally antagonistic interaction between 5-HT1A and 5-HT2A recep-
tors in thermoregulation15.
In addition to those approved and potential therapeutic applica-
tions16–19, some serotonergic agents are also used for recreational
purposes, including 5-HT receptor agonists (e.g., 5-methyoxy-N,
N-dimethyltryptamine or 5-MeO-DMT, a non-selective 5-HT
receptor agonist acting on 5-HT1A, 5-HT2A and 5-HT2C receptors
with moderate to high afﬁnities) and MAOIs (e.g., harmaline)19–22.
Co-abuse or overdose of serotonergic drugs results in excessive
serotonergic signaling and, subsequently, in life-threatening ser-
otonin toxicity or syndrome that has become an important clinical
problem16,17,23. Indeed several cases of serotonin toxicity related
to harmaline and 5-MeO-DMT drug-drug interactions (DDI) have
been documented in recent years24–26. Serotonin toxicity/syn-
drome is featured by neuromuscular (e.g., tremor and hyperre-
ﬂexia), autonomic (e.g., hyperthermia) and mental (e.g., confusion
and hyperactivity) effects in humans and animal models, among
which excessive hyperthermia (e.g., over 41.0 1C) may lead to avariety of abnormalities (e.g., metabolic acidosis and renal failure)
and even fatality.
Our recent studies on 5-MeO-DMT and harmaline DDI using
wild-type and cytochrome P450 2D6 (CYP2D6) humanized (Tg-
CYP2D6) mouse models have demonstrated that co-administration
of MAOI harmaline largely alters the pharmacokinetics (PK) of
5-MeO-DMT27–29. The status of CYP2D6, which metabolizes
both harmaline and 5-MeO-DMT, may further inﬂuence the PK
interactions between harmaline and 5-MeO-DMT29. In addition,
pretreatment with harmaline, which itself induces hypothermia30,
greatly enhances 5-MeO-DMT–elicited pharmacodynamics (PD)
as indicated by the hyperthermic effects31. To better understand
and quantitatively describe the PK/PD interplay between harma-
line and 5-MeO-DMT in thermomodulation, we developed a
mechanism-based mathematical model to characterize the thermo-
modulatory effects of serotonergic drugs in mice. This PK/PD
model consisted of an indirect response (IDR) model with
mechanistic actions of serotonergic harmaline and 5-MeO-DMT
in central thermoregulation, the pharmacokinetic DDI between
harmaline and 5-MeO-DMT, and the inﬂuence of CYP2D6 status.
The developed and qualiﬁed model not only captured simple hypo/
hyperthermia and complex biphasic effects induced by serotoner-
gic drugs and stress factors, but also identiﬁed harmaline as the
major cause of hyperpyrexia induced by toxic doses of harmaline
and 5-MeO-DMT.2. Material and methods
2.1. Chemicals and materials
Harmaline hydrochloride dihydrate and 5-MeO-DMT oxalate were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Isoﬂurane
(AErrane) was bought from Baxter Healthcare (Deerﬁeld, IL, USA).
2.2. Animals
Age-matched male wild-type FVB/N and Tg-CYP2D6 mice
(25–35 g) were used in the study. Animals were housed in an
animal care facility maintained at 2072.0 1C on a 12-h light/dark
cycle (lights on 6 a.m.–6 p.m.) with food and water provided ad
libitum. All animal procedures were approved by the Institutional
Animal Care and Use Committee at University at Buffalo, The
State University of New York, USA.
Implantation of sterile telemetric transmitter (Physiotel implant
TA10TA-F20 system; Data Sciences International, St. Paul,
MN, USA) and intraperitoneal (i.p.) administration of harmaline,
Figure 1 The PK/PD model for thermoregulation by serotonergic
drugs harmaline and 5-MeO-DMT in wild-type and Tg-CYP2D6 mice.
Abbreviations of Harmaline and 5-MeO-DMT PK parameters as well
as thermoregulation PD parameters are deﬁned under Materials and
Methods. Model estimates are shown in Table 1.
X.-L. Jiang et al.4945-MeO-DMT or control vehicle were conducted as previously
described31. Drugs were dissolved in saline and all doses were
calculated as free bases and administered in the same volume
(10 mL/kg).
2.3. Core body temperature measurement
All measurements were performed in an isolated and quiet room with
an ambient temperature maintained at 2072.0 1C31. Core body
temperatures (CBTs) of animals kept in home cages were continuously
measured (10 times per minute) using the DSI PhysioTel telemetry
system (Data Sciences International, St. Paul, MN, USA). Average
CBT values every 5 or 10 min were calculated for PK/PD modeling.
Basal level of CBT of each animal involved in this study was also
determined before the test/drug administration.
2.4. Pharmacokinetic/pharmacodynamic modeling
The PK interaction between harmaline and 5-MeO-DMT was
described by our group recently27 and was adopted in the current
study to characterize the PK proﬁles of 5-MeO-DMT when adminis-
tered alone or in combination with harmaline. Brieﬂy, a two
compartment-model, with ﬁrst order absorption and linear elimination
by CYP2D6 and inherited murine elimination pathways, was used to
describe the PK properties of harmaline in both genotypes of mice,
where CC–H represents harmaline concentration in the central compart-
ment and XP–H represents the mass of harmaline in the peripheral
compartment. VC–H (2.43 L/kg) and VP–H (2.86 L/kg) are the volumes
of central and peripheral compartment, respectively. CLD–H (0.879
L/min/kg) is the distribution clearance between the central and peripheral
compartments. ka–H (0.307 min
1) represents the absorption rate
constant, and FH represents the bioavailability of harmaline. FH values
for i.p.-dosed 2, 5 and 15 mg/kg of harmaline were 34.6%, 74.2%
and 90.3%, respectively, in wild-type mice; the values were 36.8%,
68.8% and 80.1%, respectively, in Tg-CYP2D6 mice. CLother–H (0.0962
L/min) represents the intrinsic murine elimination pathways, which is
shared by both wild-type and Tg-CYP2D6 mice, whereas CLCYP2D6–H
(0.0608 L/min) represents CYP2D6-mediated elimination that is only
present in Tg-CYP2D6mice. Likewise, a two compartment model with
ﬁrst order absorption and capacity-limited elimination from the central
compartment has been established to describe the PK properties of
5-MeO-DMT, where CC–M represents the concentration of 5-MeO-
DMT in central compartment and XP–M represents the mass of 5-MeO-
DMT in peripheral compartment. VC–M (0.460 L/kg) and VP–M (2.29
L/kg) are the volumes of central and peripheral compartment,
respectively. CLD–M (0.301 L/min/kg) is the distribution clearance
between the central and peripheral compartments. ka–M (0.0748 min
1)
represents the absorption rate constant while FM (74.8%) represents the
bioavailability of 5-MeO-DMT. Vmax(M)–M (2.69 μmol/min/kg),
Vmax(O)–M (0.0610 μmol/min/kg) and Vmax(D)–M (0.0334 μmol/min/kg)
represent the maximum metabolic rates of 5-MeO-DMT by MAO-A,
other murine elimination pathway and O-demethylation pathway,
respectively. Km(M)–M (16.7 μmol/L), Km(O)–M (0.446 μmol/L) and
Km(D)–M (1.27 μmol/L) represent the concentration of 5-MeO-DMT
at 50% of the maximum metabolism by MAO-A, other murine
elimination pathway and O-demethylation pathway, respectively. A
fmCYP2D6(D)–M value (30.1%), which only presents in Tg-CYP2D6
mice, was used to describe the fraction of 5-MeO-DMT O-demethyla-
tion by CYP2D6 in addition to murine 5-MeO-DMT O-demethylase
capacity. Ki(M)–H (0.048 μmol/L) was obtained from literature32, which
represents inhibition constant for harmaline against MAO-A. Ki(D)–H(7.13 μmol/L) was obtained from our PK model ﬁtting, which
represents inhibition constant for harmaline against 5-MeO-DMT O-
demethylase activity. Values of respective PK parameters were taken
from our recent PK interaction study27, and the resulting PK proﬁles
were used as the PK input for PD modeling to drive thermoregulation
(Fig. 1). The ﬁnal integrated PK/PD model for thermoregulatory effects
of harmaline and 5-MeO-DMT is shown in Fig. 1.
The CBT baseline (Tempbasal) was described by a linear
function Eq. (1), in which Tempbasal(0) represents the basal level
CBT and slope λ deﬁnes the inﬂuence of time on baseline CBT.
Tempbasal ¼ Tempbasalð0Þ þ λ  t ð1Þ
An indirect response model with a feedback mechanism33 was
employed to characterize the turnover of CBT as well as the
adaptive feedback mechanism of the body to the change in body
temperature, as shown in the following differential Eq. (2):
dTemp
dt
¼ kin 
Tempbasal
Temp
 
kout  Temp ð2Þ
where kin and kout represent the production and loss of heat,
respectively; Temp(0) equals to Tempbasal(0). The adaptive function
of the body to thermoregulation is described as a ratio of baseline
(Tempbasal) to response (Temp) that affects thermogenesis (kin)
33.
At time zero of the observation period, the system was assumed to
be at its physiological steady state that yields the following
baseline Eq. (3):
Tempbasalð0Þ ¼
kin
kout
ð3Þ
The stress to animal caused by handling and injection affects
thermoregulation by stimulating thermogenesis (kin)
5,34,35. This
placebo effect was best described by a hypothetical signal (SS(t))
Thermoregulatory effects of serotonergic drugs in mice 495that wears off at a rate kel–S as time progresses in Eq. (4):
SS tð Þ ¼ S0  e kel S t ð4Þ
The same S0 value was used for the hypothetical magnitude of
stress on thermoregulation by any vehicle/saline, because our data
already revealed that experimentally-induced stress level was
vehicle-independent. A ﬁrst-order rate constant kel–S was used to
describe the loss of this stress over time. This equation is similar to
the stress function reported elsewhere6.
The thermoregulatory effects of harmaline and 5-MeO-DMT
are described by the following equations, with an assumption that
harmaline and 5-MeO-DMT concentrations in the biophase (effect
site) are in rapid equilibration with those in serum (central
compartment). 5-HT1A receptor acts as a central vasodepressor,
which facilitates heat loss36. Therefore, activation of 5-HT1A
receptor on hypothermia SH(t) was expressed as stimulation of
kout, as shown in Eq. (5).
SH tð Þ ¼ kSH  CCHðtÞ ð5Þ
where kS–H represents a sensitivity constant of harmaline on kout,
which is different between single dose treatment (kS–H-single) and
combination treatment (kS–H-DDI), given the observation that DDI
interrupted the hypothermic effect of harmaline (5-MeO-DMT or
saline was dosed 15 min after the administration of harmaline).
Although our previous study employed an Emax model to characterize
the rectal temperature change in mice induced by harmaline alone30,
a linear function was found sufﬁcient to appropriately describe the
change of core body temperature in mice in the present study.
The stimulation effect of 5-MeO-DMT (SnM, n¼1, 2, 3) on
thermogenesis (kin) was best described using a transduction model
with three transit compartments (6–8)37, which accurately char-
acterized the delay between 5-MeO-DMT-induced 5-HT2A recep-
tor activation and change in CBT.
dS1M
dt
¼ 1
τ
SmaxM  CCM tð Þ
SC50M þ CCM tð Þ
S1M
 
; ðS1Mð0Þ ¼ 0Þ ð6Þ
dS2M
dt
¼ 1
τ
ðS1MS2MÞ; ðS2Mð0Þ ¼ 0Þ ð7Þ
dS3M
dt
¼ 1
τ
ðS2MS3MÞ; ðS3Mð0Þ ¼ 0Þ ð8Þ
where τ represents the mean transit time in each transit compart-
ment, and Smax–M represents the maximum stimulation effect of
5-MeO-DMT on thermogenesis. SC50–M represents the concentra-
tion of 5-MeO-DMT that produces 50% of the maximum
stimulatory effect, which is different when 5-MeO-DMT was
dosed with (SC50–M-DDI) or without (SC50–M-non-DDI) the presence
of harmaline. The ﬁnal thermoregulatory model is shown in Eq.
(9), which is derived from Eq. (2):
dTemp
dt
¼ kin 
Tempbasal
Temp
 
 1þ SS tð Þð Þ  1þ S3M tð Þð Þ
kout  1þ SH tð Þð Þ  Temp ð9Þ
where Temp(0) equals to Tempbasal(0). All model ﬁttings were
performed in ADAPT V (Biomedical Simulations Resource,
University of Southern California, Los Angeles, CA, USA) with
a naïve-pooled population analysis. All PK parameters27 were
ﬁxed and linked to PD model. PD model parameters were obtained
by simultaneous estimation of CBT proﬁles at physiological
conditions with the maximum-likelihood method38, which
included no treatment (baseline), control vehicles, harmaline alone
(2, 5 and 15 mg/kg), 5-MeO-DMT alone (2, 10 and 20 mg/kg),harmaline (2, 5 and 15 mg/kg) plus vehicle, vehicle plus 5-MeO-
DMT (2, 10 and 20 mg/kg), and harmaline (2, 5 and 15 mg/kg)
plus 5-MeO-DMT (2 mg/kg) treatments.
Different PD model structures were tested during model
development, which included an IDR model with or without
transit compartments, an IDR model with different numbers of
transit compartments, DDI and non-DDI conditions with different
or the same parameters (kS–H, Smax–M, SC50–M), and the inﬂuence
of concurrent harmaline on 5-MeO-DMT (Smax–M or SC50–M)
when the PD interaction was considered. Model selection was
based on goodness-of-ﬁt criteria, which included model conver-
gence, Akaike Information Criterion (AIC), Schwarz Criterion
(SC), precision of parameter estimations, estimation criterion value
for the maximum likelihood method, visual inspection of predicted
versus observed values, and residual plots as well as physiological
plausibility and statistical signiﬁcance of model parameter esti-
mates. Different variance models were also tested during model
development and the ﬁnal variance model was deﬁned as
VARi ¼ ðσ1þσ1  Yðθ; tiÞÞ2 ð10Þ
where σ1 and σ2 are the variance model parameters and Y(θ, ti) is
the ith predicted value from the PK/PD model.
This developed PK/PD model was externally validated by
comparing the simulated and experimentally-determined CBT proﬁles
in mice treated with 10 mg/kg of harmaline alone, 5 mg/kg of
5-MeO-DMT alone, and 5 mg/kg of harmaline plus 5 mg/kg of
5-MeO-DMT that were all proven non-toxic by our previous27 and
pilot studies. The qualiﬁed model was further utilized to investigate
the interactions between harmaline (2, 5 or 15 mg/kg) and 5-MeO-
DMT (10 mg/kg), which was shown to be toxic to both genotypes of
mice27,31,39. Simulations of harmaline and 5-MeO-DMT PK proﬁles
were also conducted using our PK DDI model described recently27.3. Results
3.1. PK/PD model development and estimation
Our ﬁnal model (Fig. 1) was able to characterize all experimental
effect-time proﬁles in the presence or absence of single or
combination drug treatment reasonably well (Figs. 2–4). Respec-
tive models parameters were estimated with good precision that
was indicated by the low CV (%) values (Table 1). A simple linear
function Eq. (1) was found to be sufﬁcient to appropriately
characterize the baseline temperatures in both Tg-CYP2D6 and
wild-type mice during the observation time frame (10:30 a.m.–
3:30 p.m., Fig. 2). The estimated Tempbasal(0) was 35.8 1C and λ
was 0.00322 1C/min, which indicates a slow but steady increase of
baseline CBT during the light phase of the light/dark circle.
The modiﬁed IDR model consisting of a feedback mechanism
(Fig. 1) adequately described the thermoregulation in response to
injection/handling stress and serotonergic drug perturbation, estimating
a kout value of 0.0291 min
1 (Table 1). Vehicle treatment consistently
caused a mild transient hyperthermia that was initiated rapidly, whereas
it was independent of drug treatment (Figs. 2–4). The estimated S0 and
kel–S values were 0.265 and 0.103 min
1, respectively (Table 1), which
reasonably described the hyperthermia of animals induced by single or
repeated handling and injection (Fig. 2). Nevertheless, animal handling
could alter harmaline-induced hypothermia (Fig. 4A and 4B versus
Fig. 3A and 3B), which resulted in a kS-H value of 0.0347 L/μmol for
single treatment (kS–H-single) and 0.0136 L/μmol for repeated treatments
(kS–H-DDI) (Table 1).
Figure 2 Model estimation of CBT proﬁles in wild-type (A) and Tg-CYP2D6 (B) mice (n¼26 in each group) at the baseline level (circle) or
after single (triangle) or double (square) injections of saline. The solid (─), dashed (- -) and dotted (   ) lines represent the ﬁtted data of baseline,
single and double injections of saline, respectively, which were obtained from simultaneous estimation using the PK/PD model shown in Fig. 1.
CBT, core body temperature.
Figure 3 Model estimation of the hypothermia (A and B) and hyperthermia (C and D) in mice induced by harmaline and 5-MeO-DMT alone,
respectively. Harmaline or 5-MeO-DMT was administered i.p. to wild-type and Tg-CYP2D6 mice (n¼14 in each group) at 0 min. The solid (─),
dashed (- -) and dotted (   ) lines represent the ﬁtted data with the ascending doses of respective drugs, which were obtained from simultaneous
estimation using the PK/PD model shown in Fig. 1.
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Figure 4 Model estimation of the thermomodulatory effects in mice co-administered with harmaline and 5-MeO-DMT, including harmaline plus
vehicle (A and B), vehicle plus 5-MeO-DMT (C and D), and various doses of harmaline plus 2 mg/kg 5-MeO-DMT (E and F) in wild-type (n¼11)
and Tg-CYP2D6 (n¼12) mice. Harmaline and 5-MeO-DMT or corresponding vehicle were administered i.p. at 0 and 15 min, respectively. The
solid (─), dashed (- -) and dotted (   ) lines represent the ﬁtted data with the ascending doses of respective drugs, which were obtained from
simultaneous estimation using the PK/PD model shown in Fig. 1.
Thermoregulatory effects of serotonergic drugs in mice 4975-MeO-DMT alone stimulated hyperthermia (Figs. 3 and 4) with
a transit time of 6.20 min for each of the 3 transit compartments, an
Smax–M value of 0.134, and an SC50–M–non-DDI value of 1.88 μmol/L
(Table 1). Co-administration of harmaline with 2 mg/kg 5-MeO-DMT
provoked biphasic effects, hypothermia at early phase (0–45 min) and
hyperthermia at late phase (45–120 min), which was captured well
by current PK/PD model (Fig. 4). Furthermore, co-administered
harmaline signiﬁcantly enhanced 5-MeO-DMT–induced late-phase
hyperthermia that was adequately described by a decreased
SC50–M-DDI value (0.496 μmol/L; Table 1) in this model. As
expected, the inﬂuence of CYP2D6 status on harmaline PK and
harmaline-5-MeO-DMT PK interaction27 might be translated intosigniﬁcant difference in PD, which was manifested by the greater
and prolonged hypothermia in wild-type mice following harmaline
treatment (Figs. 3A, 3B, 4A and 4B) or co-administration of
15 mg/kg harmaline and 2 mg/kg 5-MeO-DMT (Fig. 4E and F), in
contrast to the similar hyperthermic effects in two genotypes of
mice treated with 5-MeO-DMT alone (Figs. 3C, 3D, 4C and 4D).3.2. Model validation
The CBT proﬁles of animals treated with 10 mg/kg harmaline,
5 mg/kg 5-MeO-DMT, and 5 mg/kg harmaline plus 5 mg/kg
Table 1 Pharmacodynamic parameters of harmaline and 5-MeO-DMT in thermoregulation.
Parameter Unit Deﬁnition Estimated value CV (%)
Tempbasal(0) 1C Baseline core body temperature at the beginning of the experiment 35.8 0.0454
λ 1C/min The slope of change of baseline core body temperature 0.00322 4.79
τ min Transit time in teach compartment 6.20 5.86
kout min
1 Rate constant of loss of heat 0.0291 4.44
S0 – Hypothetic magnitudes of stress on thermoregulation 0.265 5.75
kel–S min
1 Rate constant of elimination of stress 0.103 6.46
kS–H-single L/μmol Sensitivity constant of harmaline on thermogenesis after single dosing regimen 0.0347 1.80
kS–H-DDI L/μmol Sensitivity constant of harmaline on thermogenesis after DDI dosing regimen 0.0136 2.86
Smax–M – The maximum stimulation effect of 5-MeO-DMT on thermogenesis 0.134 4.28
SC50–M-non-DDI μmol/L The concentration of 5-MeO-DMT producing 50% of the maximum stimulation effect
when treated alone or pretreated with vehicle
1.88 12.8
SC50–M-DDI μmol/L The concentration of 5-MeO-DMT producing 50% of the maximum stimulation effect
when pretreated with harmaline
0.496 12.2
X.-L. Jiang et al.4985–MeO-DMT that did not induce any signiﬁcant toxicity in mice,
were used to validate the developed PK/PD model under nontoxic
physiological conditions. The simulated CBT proﬁles (Fig. 5)
using the PK/PD model (Fig. 1) and estimated PD parameters
(Table 1) reasonably captured the experimental data obtained in
mice. Similar to the dose levels of harmaline utilized for
model development, a single dose of harmaline (10 mg/kg)
alone induced more severe hypothermia in wild-type mice than
Tg-CYP2D6 mice (Fig. 5A and B), whereas 5-MeO-DMT (5 mg/
kg) alone had similar thermomodulatory effects in the two
genotypes of mice (Fig. 5C and D). On the other hand, co-
administration of harmaline (5 mg/kg) with 5-MeO-DMT (5 mg/
kg) led to a prolonged hyperthermia in wild-type mice (Fig. 5E
and F). The results indicate that the present PK/PD model is able
to quantitatively characterize the thermomodulatory effects of
serotonergic harmaline and 5-MeO-DMT under physiological
conditions.3.3. Application of the developed PK/PD model for evaluating
hyperpyrexia induced by toxic dose combinations of 5-MeO-DMT
and harmaline
Higher dose combinations of harmaline (5 or 15 mg/kg) and
5-MeO-DMT (10 mg/kg) are toxic to both genotypes of
mice27,31,39 (and unpublished data). Such dose combinations
caused a rapid increase of CBT (15–75 min) to an extremely high
level (e.g., 439 1C) in mice (Fig. 6), indicating a transition to
toxicokinetic/toxicodynamic (TK/TD) interactions between harma-
line and 5-MeO-DMT. In contrast, the treatment with 2 mg/kg
harmaline plus 10 mg/kg 5-MeO-DMT led to a maximal CBT
around 38 1C, suggesting that DDI of harmaline and 5-MeO-DMT
at this dose combination remained as nontoxic to mice. Consis-
tently, the validated PK/PD model described herein (Fig. 1)
reasonably predicted the changes of CBT in both genotypes
of mice following the treatment with 2 mg/kg harmaline plus
10 mg/kg 5-MeO-DMT (Fig. 6A and B), whereas the PK/PD
model was unable to describe the CBT proﬁles in mice treated
with toxic dose combinations of harmaline (5 or 15 mg/kg) and
5-MeO-DMT (10 mg/kg), including the rapid increase of CBT at
early times (15–75 min) and quick decline during the late stage
(Fig. 6C–F). These results suggest that the physiological thermo-
regulation in mice may be disrupted by toxic doses of serotonergic
harmaline and 5-MeO-DMT (Fig. 6).4. Discussion and conclusions
It has been shown that MAOI harmaline signiﬁcantly enhances
5-MeO-DMT–induced hallucinogenic effects and toxicity21,24–26.
Recent studies also demonstrate the inﬂuence of harmaline on
5-MeO-DMT–elicited neuropharmacological effects in animal
models including thermoregulation and behaviors31,39–43 as well
as 5-MeO-DMT pharmacokinetics27,29,43. In the present study, a
mathematical PK/PD model, which consists of an IDR model with
baseline behavior, the adaptive feedback mechanism of the
biological system, the impact of stress caused by handling and
injection, and mechanistic actions of serotonergic drugs in
thermomodulation, was developed and validated to characterize
the relationship between drug concentrations and modulation of
CBT by harmaline and 5-MeO-DMT, administered alone or in
combination. This PK/PD model provides a quantitative explana-
tion for the PK and PD DDIs between harmaline and 5-MeO-
DMT, and it should have broad applications to the prediction of
thermoregulation by serotonergic drugs.
A set-point model has been developed previously to describe
the oscillatory behavior of CBT in rats by a series of hypothermic
5-HT1A agents
44,45. Another set-point model was developed to
characterize interleukin-21–induced hyperthermia in cynomolgus
monkeys46. While both compounds examined in the present study
were serotonergic drugs, they did not cause any signiﬁcant
oscillation in mice at tested doses. Therefore, a simple
mechanism-based IDR model was employed to deﬁne thermo-
regulation, which nicely characterized drug-induced changes of
CBT in mice via the modulation of either thermogenesis (kin) or
heat loss (kout). 5-MeO-DMT acts mainly as a 5-HT2A agonist
under pharmacological conditions despite that it can bind to
multiple 5-HT receptors47,48. In addition, the effect of tested doses
of 5-MeO-DMT on 5-HT1A receptor may be minimal, given
previous ﬁnding that 5-MeO-DMT is less potent than 5-HT in
terms of binding to 5-HT1A receptor
49, and murine cerebral
5-MeO-DMT concentrations were also remarkably lower than
5-HT following the administration of 5-MeO-DMT (2 or 10 mg/kg)
alone or combined with harmaline (5–20 mg/kg)27,50. Therefore,
only the activation of 5-HT2A receptor was considered in the present
PK/PD model for thermogenesis (Fig. 1). On the other hand, the
heat loss was simply attributed to 5-HT1A activation by harmaline-
induced increase of 5-HT levels50. The simpliﬁcation was made as
harmaline-induced hypothermia was only attenuated by 5-HT1A
receptor antagonist31.
Figure 5 Comparison of experimental and model predicted CBT proﬁles in wild-type and Tg-CYP2D6 mice treated with 10 mg/kg harmaline
alone (A and B; n¼14 in each group), 5 mg/kg 5-MeO-DMT alone (C and D; n¼4 in each group), and 5 mg/kg harmaline plus 5 mg/kg 5-MeO-
DMT (E and F; n¼4 in each group). For single dose study, drug was dosed i.p. at 0 min. For DDI study, harmaline and 5-MeO-DMT were dosed
i.p. at 0 and 15 min, respectively. The solid (─) lines represent the predicted data that were obtained from the developed PK/PD model shown in
Fig. 1.
Thermoregulatory effects of serotonergic drugs in mice 499An adaptive negative feedback mechanism33, which was
described as the ratio of baseline (Tempbasal) to response (Temp)
that regulates thermogenesis (kin), was incorporated into this IDR
model to capture the inﬂuence of serotonergic drugs on the
homeostasis of CBT. Because wild-type and Tg-CYP2D6 mice
share the same genetic background51 and the only difference is the
expression of human drug-metabolizing enzyme CYP2D6 in the
Tg-CYP2D6 mice, the variation in PD response is simply
attributable to CYP2D6-caused differences in harmaline-5-MeO-DMT PK that drives the IDR. Therefore, the same set of PD
parameters was used for wild-type and Tg-CYP2D6 mice. Indeed,
the present PK/PD model sufﬁciently described the thermoregula-
tory effects of harmaline and 5-MeO-DMT in both genotypes of
mice. Single or multiple injections of control vehicle initiated
similar transient hyperthermic effects in mice, and there were no
signiﬁcant differences in the change of CBT proﬁles (Fig. 2) and
area under effect curve values (about 7% difference). Therefore,
the same post-injection hyperthermic component (S0 and kel–s) was
Figure 6 Comparison of experimental and model simulated CBT proﬁles in wild-type (n¼11) and Tg-CYP2D6 (n¼12) mice treated with 2 (A
and B), 5 (C and D) or 15 mg/kg (E and F) harmaline plus 10 mg/kg 5-MeO-DMT. Harmaline and 5-MeO-DMT were dosed i.p. at 0 and 15 min,
respectively. The solid (─) lines represent the predicted data that were obtained from the developed PK/PD model shown in Fig. 1.
X.-L. Jiang et al.500applied to describe such stress-induced hyperthermia (Fig. 2).
Nevertheless, the handling/injection in the DDI studies (vehicle or
5-MeO-DMT administered 15 min after harmaline) signiﬁcantly
affected harmaline-induced hypothermia (Figs. 3A and B, 4A and
B) by reducing the kS–H more than 50% (0.0347–0.0136 L/μmol,
Table 1) in mice.
Given the observation that there was a delay in the appearance
of hyperthermia through the activation of 5-HT2A receptor, in
contrast to an immediate onset of hyperthermia induced by
handling/injection, a separate component was utilized to charac-
terize 5-HT2A agonist–stimulated thermogenesis (kin) (Fig. 1). The
delay was described by three transit compartments that may beassociated with the signal transduction processes from central 5-
HT2A receptor activation to peripheral systems, heat generation in
iBAT and skeletal muscle as well as the thermoregulatory
response5,7. The mean transit time (τ) in each compartment was
estimated to be around 6.2 min. The activation of 5-HT2A receptor
was shown to stimulate thermogenesis with an SC50–M–non-DDI
value of 1.88 μmol/L, which is close to the binding afﬁnity
(0.9–1.5 μmol/L) of 5-MeO-DMT to human 5-HT2A receptor
reported previously49,52.
Current PK/PD model adequately captured and predicted the
CBT proﬁles including biphasic effects in all mice treated with
nontoxic doses of 5-MeO-DMT in the absence and presence of
Figure 7 Model predicted serum harmaline (A and B) and 5-MeO-DMT (C and D) concentration versus time proﬁles following the
administration of 2, 5 or 15 mg/kg harmaline plus 10 mg/kg 5-MeO-DMT, or 20 mg/kg 5-MeO-DMT alone in wild-type and Tg-CYP2D6 mice.
Harmaline and 5-MeO-DMT were dosed i.p. at 0 and 15 min, respectively. The solid (─), dashed (- -) and dotted (   ) lines represent the simulated
data of harmaline and 5-MeO-DMT in mice treated with ascending doses of harmaline (2–15 mg/kg) plus 10 mg/kg 5-MeO-DMT, while the
dashed plus dotted (-  -) lines represent 5-MeO-DMT proﬁles in mice treated with 20 mg/kg 5-MeO-DMT alone. The PK proﬁles were obtained
using our previously established PK DDI model27 that is also shown in Fig. 1.
Thermoregulatory effects of serotonergic drugs in mice 501harmaline (Figs. 4 and 5), supporting the utility of mathematical
modeling in quantitative neuropharmacology. The PK/PD model-
ing also revealed that 5-MeO-DMT–induced hyperthermia
enhanced by MAOI harmaline was partly driven by the increased
exposure to 5-MeO-DMT (Fig. 7). The potentiation of hyperther-
mia was indicated by the lower SC50–M-DDI value (0.496 μmol/L)
estimated by the current PK/PD model, which was almost a 4-fold
enhancement of hyperthermic potency than 5-MeO-DMT alone
(SC50–m-non-DDI, 1.88 μmol/L). The interaction at PD level may be
associated with the elevation of 5-HT by MAOI harmaline50.
Additionally, several studies have shown that harmaline may
directly bind to multiple neurotransmitter receptors including
5-HT, norepinephrine (NE), dopamine D2/D3 and N-methyl-D-
aspartate (NMDA) glutamate receptors and/or modulate cerebellar
glutamatergic transmission53–57.
The validated PK/PD model was further employed to evaluate
the hyperpyrexia caused by toxic doses of harmaline and 5-MeO-
DMT (Fig. 6). Comparison of simulated and experimental CBT
proﬁles revealed that the present PK/PD model reasonably predicted
the thermoregulatory effects of 2 mg/kg harmaline plus 10 mg/kg
5-MeO-DMT (Fig. 6A and B). However, this PK/PD model
underestimated the early-stage sharp increase of CBT and over-
estimated the late-stage decrease of CBT in mice treated with toxicdose combinations of harmaline (5 or 15 mg/kg) and 5-MeO-DMT
(10 mg/kg) (Fig. 6C–F), suggesting that severe serotonin toxicity
might signiﬁcantly disrupt physiological thermoregulation. Interest-
ingly, the early-time (0–60 min) systemic exposure to 10 mg/kg
5-MeO-DMT only increased by 20% when harmaline dose was
increased from 2 to 15 mg/kg, according to the observed27 and
simulated PK proﬁles (Fig. 7C and D). Given the estimated EC50
values for 5-MeO-DMT (1.88 and 0.496 μmol/L under 5-MeO-
DMT alone or DDI condition, respectively) in inducing hyperther-
mia and a much higher serum drug concentration (48 μmol/L,
Fig. 6), a full stimulation of the 5-HT2A receptor would be expected.
Therefore, the potentiation of 5-MeO-DMT–induced hyperthermia
was presumably related to harmaline actions. Indeed, systemic
exposure to harmaline was elevated almost 20-fold when the doses
of harmaline were increased from 2 to 15 mg/kg (Fig. 7A and B).
Under such toxic drug combination conditions, the highly elevated
levels of 5-HT and other monoamine neurotransmitters following
harmaline-dictated inhibition of MAO, as well as the excessive
stimulation of multiple neurotransmitter receptors by harmaline
itself50,53–56, would be the major causes of serotonin toxicity
including the hyperpyrexia underestimated by current model.
In summary, an integrated PK/PD model was developed in this
study and it was able to quantitatively characterize and predict the
X.-L. Jiang et al.502impact of serotonergic drugs on thermoregulation in mice. This
model consisted of mechanistic activation of 5-HT receptors in the
control of thermogenesis and heat loss. The current model also
described the complex biphasic effects including the potentiation
of 5-MeO-DMT–induced late-phase hyperthermia by co-
administered MAOI harmaline after considering their interactions
at both PD and PK levels, i.e., acting on the same serotonergic
system and enhancing systemic exposure to 5-MeO-DMT and
5-HT. In addition, our ﬁndings indicated that the hyperpyrexia
caused by high dose combination of harmaline and 5-MeO-DMT
was mainly attributed by the exposure to harmaline. This
mechanism-based PK/PD model may serve as a new framework
for the investigation of thermoregulatory or other neuropharma-
cological effects of serotonergic agents.Acknowledgments
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